Northern Trust
MTCR

Northern Trust’s Metacrine, Inc. Common Stock MTCR Stock Holding History

Northern Trust’s Portfolio MTCR Stock Details MTCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-26,163
Closed -$11.7K – 4682
2022
Q4 		$11.7K Hold
26,163
– – ﹤0.01% 4560
2022
Q3 		$13K Buy
26,163
+9,524
+57% +$4.68K ﹤0.01% 4616
2022
Q2 		$8K Hold
16,639
– – ﹤0.01% 4711
2022
Q1 		$10K Hold
16,639
– – ﹤0.01% 4699
2021
Q4 		$11K Hold
16,639
– – ﹤0.01% 4738
2021
Q3 		$57K Buy
16,639
+4,408
+36% +$13.7K ﹤0.01% 4513
2021
Q2 		$46K Sell
12,231
-59,577
-83% -$246K ﹤0.01% 4507
2021
Q1 		$445K Sell
71,808
-5,840
-8% -$51.7K ﹤0.01% 3853
2020
Q4 		$611K Buy
+77,648
New +$712K ﹤0.01% 3667

Other funds holding MTCR

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Northern Trust's MTCR Position: Q1 2023 in Review

Northern Trust sold out of Metacrine, Inc. Common Stock (MTCR) in Q1 2023, closing a stake of 26,163 shares — an estimated $11.7K sold.

Northern Trust first reported a position in MTCR in Q4 2020 and held it in 9 quarters. The position peaked at $611K in Q4 2020. 5 funds tracked by Wall St. Rank hold MTCR as of Q1 2023.

  • Northern Trust reported no remaining Metacrine, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Northern Trust sold 26,163 Metacrine, Inc. Common Stock shares in Q1 2023, an estimated $11.7K.
  • Northern Trust first reported a position in Metacrine, Inc. Common Stock in Q4 2020 and held it in 9 quarters.
  • Northern Trust's Metacrine, Inc. Common Stock position peaked at $611K in Q4 2020.
  • 5 funds tracked by Wall St. Rank held Metacrine, Inc. Common Stock as of Q1 2023.

Based on Northern Trust's 13F filing for Q1 2023, filed 15 May 2023.